Related Experiment Video

Updated: Jun 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

Dora Dias-Santagata1, Sara Akhavanfard, Serena S David

  • 1Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. ddiassantagata@partners.org

EMBO Molecular Medicine
|May 1, 2010
PubMed

Insights

This study developed a rapid, cost-effective, high-throughput genotyping platform for identifying cancer mutations. This enables personalized cancer therapy selection and improves patient management through real-time genetic profiling.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Diagnostics

Background:

  • Targeted cancer therapies rely on precise identification of genetic mutations.
  • Existing methods for genetic profiling can be slow and costly, hindering timely patient selection for optimal treatment.

Purpose of the Study:

  • To create a high-throughput genotyping platform for rapid and accurate identification of cancer-related genetic mutations.
  • To enable prospective patient selection for targeted cancer therapies.
  • To develop an assay easily adoptable by clinical laboratories.

Main Methods:

  • Developed a sensitive, multiplexed clinical assay for detecting 120 mutations in 13 cancer genes.
  • Validated the assay using nucleic acid from formalin-fixed, paraffin-embedded (FFPE) tissues.
  • Performed genetic profiling on 250 primary tumor samples.

Main Results:

  • The assay demonstrated high sensitivity and performance with FFPE tissues.
  • Genetic profiling results aligned with known oncogene mutation spectra.
  • Rare genetic events were identified in specific cancer types.
  • The assay is currently in clinical use for patient management.

Conclusions:

  • Established a widely adoptable platform for real-time targeted genotyping in cancer.
  • The platform facilitates personalized cancer treatment strategies.
  • This approach is expected to significantly impact future cancer management.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...